Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | DRD1 | P21728 | 13/20 | 0.42 |
| ▸ | DRD5 | P21918 | 12/20 | 0.42 |
| ▸ | DRD2 | P14416 | 11/20 | 0.38 |
| ▸ | DRD4 | P21917 | 11/20 | 0.38 |
| ▸ | DRD3 | P35462 | 11/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214352 | 0.95 | MAOA (0.46) | MAOAMAOBDRD1DRD5DRD2 | |
| SCHEMBL218196 | 0.89 | MAOA (0.55) | MAOAMAOBDRD1DRD5DRD2 | |
| SCHEMBL578027 | 0.83 | MAOA (0.59) | MAOAMAOBDRD1DRD5DRD2 | |
| SCHEMBL213748 | 0.82 | MAOA (0.40) | MAOAMAOB | |
| SCHEMBL217306 | 0.80 | DRD2 (0.48) | MAOAMAOBDRD1DRD5DRD2 | |
| SCHEMBL23306 | 0.75 | — | — | |
| SCHEMBL22225 | 0.75 | TSHR (0.46) | — | |
| SCHEMBL28597607 | 0.75 | MEN1 (0.39) | — | |
| SCHEMBL28597675 | 0.75 | HTR7 (0.40) | MAOAMAOBDRD2DRD3 | |
| SCHEMBL1450294 | 0.74 | ALDH1A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168966-B1 | BICYCLOANILINE DERIVATIVE | MSD KK (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-8436004-B2 | Bicycloaniline derivative | MSD K.K. (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110135601-A1 | BICYCLOANILINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2011-06-09 | — | — | US | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| EP-2168966-A1 | BICYCLOANILINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135601-A1 | BICYCLOANILINE DERIVATIVE | WEE1, WEE2, CCNK | MAOA 1699/4885MAOB 1737/4885DRD1 2577/4885 |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | MAOA 2305/4885MAOB 563/4885DRD1 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.